U.S. Hospitality Stock News

NasdaqGS:PLUS
NasdaqGS:PLUSElectronic

Is It Time To Revisit ePlus (PLUS) After Recent Share Price Pullback

If you are wondering whether ePlus at around US$83.88 is offering fair value or hiding a margin of safety, you are not alone. The stock has seen short term pullbacks, with a 3.4% decline over the last 7 days and 4.3% over the last 30 days, while still sitting on a 20.0% return over 1 year and 88.4% over 5 years. These mixed returns have kept interest alive in how the market is currently sizing up ePlus, as investors weigh its recent share price softness against its longer term record. This...
NasdaqCM:RGC
NasdaqCM:RGCPharmaceuticals

Does Regencell Bioscience (RGC) Extending Insider Lock-Ups Recast Its Management Alignment Story?

Regencell Bioscience Holdings recently extended insider lock-up commitments by one year for its directors and employees, covering previously granted stock options and keeping their holdings restricted for longer. This extended lock-up concentrates ownership among insiders for an additional year, which can influence how outside investors interpret management’s conviction and alignment with shareholders. With this lock-up extension shaping insider alignment, we’ll explore how it reframes...
NYSE:WST
NYSE:WSTLife Sciences

How Investors Are Reacting To West Pharmaceutical (WST) GLP-1 Momentum And Upbeat 2026 Sales Guidance

In February 2026, West Pharmaceutical Services reported that fourth-quarter 2025 sales rose to US$805.0 million with net income of US$132.1 million, and issued 2026 guidance calling for US$3.215–3.275 billion in net sales with mid-single-digit organic growth supported by foreign-exchange tailwinds. Management highlighted strong momentum in high-value product components tied to GLP-1 therapies and biologics, alongside margin expansion from a richer product mix and a planned sale of the...
NasdaqGS:CRVL
NasdaqGS:CRVLHealthcare

CorVel’s Earnings Momentum And Buybacks Might Change The Case For Investing In CorVel (CRVL)

In February 2026, CorVel Corporation reported past third-quarter and nine-month results to December 31, 2025, showing higher sales of US$235.63 million and US$709.98 million, respectively, alongside increases in net income and earnings per share from continuing operations versus a year earlier. CorVel also disclosed that between October 1 and December 31, 2025, it repurchased 185,079 shares for US$13.4 million, bringing total buybacks under its long-running program announced in 1996 to...
NYSE:NRP
NYSE:NRPOil and Gas

Did NRP’s Affirmed 2025 Payout Reveal the True Strength of Its Capital‑Light Royalty Model?

Natural Resource Partners L.P. previously declared a fourth quarter 2025 cash distribution of US$0.75 per common unit, payable on February 24, 2026, to unitholders of record as of February 17, 2026. This distribution affirmation highlights how the partnership’s capital-light royalty model and monetization of energy transition assets are supporting ongoing cash generation. We will now examine how the affirmed distribution and capital-light royalty model shape Natural Resource Partners’...
NasdaqGM:LGND
NasdaqGM:LGNDPharmaceuticals

Assessing Ligand Pharmaceuticals (LGND) Valuation After Recent Share Price Weakness And Strong 1 Year Return

Event context and recent stock performance Ligand Pharmaceuticals (LGND) has come into focus after a period in which its shares have moved lower over the past month and past 3 months, while still showing a positive 1 year total return. At a last close of US$183.83, the company carries a value score of 3, with annual revenue of US$251.233 million and net income of US$48.581 million, supported by positive annual revenue and net income growth. See our latest analysis for Ligand...
NYSE:ATMU
NYSE:ATMUMachinery

Atmus Filtration Technologies (ATMU) Margin Expansion Reinforces Bullish Earnings Narratives

Atmus Filtration Technologies (ATMU) has capped FY 2025 with Q4 revenue of US$446.6 million and basic EPS of US$0.59. Trailing twelve month revenue landed at US$1.76 billion with EPS of US$2.52 and net income of US$207.4 million. The company has seen quarterly revenue move from US$403.7 million and EPS of US$0.53 in Q3 2024 to the current Q4 2025 levels. Trailing twelve month EPS has stepped up from US$2.16 to US$2.52 over the same comparison points, setting up a results season where...
NasdaqGS:IPGP
NasdaqGS:IPGPElectronic

IPG Photonics Leans On Defense And Medical To Redefine Growth Mix

IPG Photonics (NasdaqGS:IPGP) has introduced the CROSSBOW MINI High-Energy Laser system, a new scalable defense product aimed at countering drone threats. The company reports strong momentum in its medical business, supported by new product launches and a major customer win. Management has indicated that medical-related revenues are expected to double or triple in the next year. IPG Photonics, trading at about $153.91, has seen very strong recent share price performance, with the stock up...
NYSE:TFC
NYSE:TFCBanks

Assessing Truist Financial (TFC) Valuation After Recent Share Price Momentum And Earnings Expectations

Why Truist Financial is on investors’ radar Truist Financial (TFC) is back in focus after recent trading left the shares with a mixed return profile, including a small 1 day pullback but gains over the month and past 3 months. See our latest analysis for Truist Financial. While the 1 day share price return of a 0.33% decline to US$51.90 and the 7 day share price return of a 7.01% decline hint at some cooling after recent strength, the 30 day and 90 day share price returns of 3.82% and 18.17%...